Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

A version of meloxicam designed to work faster has beat out a placebo in two late-stage studies focused on post-surgical ...

Some providers may need to reduce services, lay off staff or close their doors if Congress enacts major cuts to the ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Already facing headwinds caused by a patient’s death and treatment delays, the biotech now may have to contend with a less ...

A vocal opponent of his predecessor Peter Marks, Vinay Prasad will now lead the office tasked with reviewing some genetic ...

Zevaskyn, which Abeona priced at $3.1 million, treats epidermolysis bullosa. It will compete with a gene therapy from Krystal ...

Sales of the company’s copycat to J&J’s blockbuster reached $150 million in the first quarter, adding to a surge in revenue ...

The Food and Drug Administration should look for ways to streamline regulations on new U.S. drug manufacturing facilities to ...